je.st
news
Home
› BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting
2014-09-07 03:43:00| Biotech - Topix.net
BioCryst Pharmaceuticals, Inc. today announced trial results related to RAPIVAB , a neuraminidase inhibitor for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C., September 5-9, 2014. "Based on clinical trial data, peramivir is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza," said presenting author Richard Whitley, M.D , University of Alabama at Birmingham.
Tags: the
results
meeting
treatment
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||